American Journal of Epidemiology Vol. 151, No. 12: 1158-1171
Copyright © 2000 by The Johns Hopkins University School of Hygiene and Public Health
other |
Mathematical Model for the Natural History of Human Papillomavirus Infection and Cervical Carcinogenesis
1Department of Obstetrics and Gynecology, Duke University Medical Center Durham, NC.
2Evidence-based Practice Center, Center for Clinical Health Policy Research, Duke University Medicine, Department of Medicine, Duke University Medical Center Durham, NC.
3Division of General Internal Medicine, Department of Medicine, Duke University Medical Center Durham, NC.
4Durham Veteran's Affairs Medical Center Durham, NC.
Reprint requests to Dr. Evan R. Myers, DUMC 3279, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710 (e-mail: myers008@mc.duke.edu).
The authors constructed a Markov model as part of a systematic review of cervical cytology conducted at the Duke University Evidence-based Practice Center (Durham, North Carolina) between October 1997 and September 1998. The model incorporated states for human papillomavirus infection (HPV), low- and high-grade squamous intraepithelial lesions, and cervical cancer stages I–IV to simulate the natural history of HPV infection in a cohort of women from ages 15 to 85 years. The age-specific incidence rate of HPV, and regression and progression rates of HPV and squamous intraepithelial lesions, were obtained from the literature. The effects of varying natural history parameters on cervical cancer incidence were evaluated by using sensitivity analysis. The base-case model resulted in a lifetime cervical cancer risk of 3.67% and a lifetime cervical cancer mortality risk of 1.26%, with a peak incidence of 81/100, 000 at age 50 years. Age-specific distributions of precursors were similar to reported data. Lifetime risk of cancer was most sensitive to the incidence of HPV and the probability of rapid HPV progression to high-grade lesions (two- to threefold variations in risk). The model approximates the age-specific incidence of cervical cancer and provides a tool for evaluating the natural history of HPV infection and cervicai cancer carcinogenesis as well as the effectiveness and cost-effectiveness of primary and secondary prevention strategies. Am J Epidemiol 2000; 151: 1158-71.
cervical intraepithelial neoplasia; cervix neoplasms; models; theoretical; papillomavirus; human
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Jit, N. Gay, K. Soldan, Y. Hong Choi, and W. J. Edmunds Estimating Progression Rates for Human Papillomavirus Infection From Epidemiological Data Med Decis Making, January 1, 2010; 30(1): 84 - 98. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Kim, J. Ortendahl, and S. J. Goldie Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States Ann Intern Med, October 20, 2009; 151(8): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Shi, J. L. Belinson, F.-H. Zhao, R. G. Pretorius, J. Li, J.-F. Ma, F. Chen, W. Xiang, Q.-J. Pan, X. Zhang, et al. Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China Am. J. Epidemiol., September 15, 2009; 170(6): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Blatter and B. J. Monk The Pediatrician's Role in Preventing Cervical Cancer Clinical Pediatrics, September 1, 2008; 47(7): 627 - 638. [PDF]
|
|
|
|
 |
|
 D S Hughes, N Powell, and A N Fiander Will vaccination against human papillomavirus prevent eye disease? A review of the evidence Br J Ophthalmol, April 1, 2008; 92(4): 460 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Fishbein, K. R. Broder, L. Markowitz, and N. Messonnier New, and Some Not-so-New, Vaccines for Adolescents and Diseases They Prevent Pediatrics, January 1, 2008; 121(Supplement_1): S5 - S14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shrestha, C. Wang, B. Aissani, C. M. Wilson, J. Tang, and R. A. Kaslow Interleukin-10 Gene (IL10) Polymorphisms and Human Papillomavirus Clearance among Immunosuppressed Adolescents Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kim, K. M. Kuntz, N. K. Stout, S. Mahmud, L. L. Villa, E. L. Franco, and S. J. Goldie Multiparameter Calibration of a Natural History Model of Cervical Cancer Am. J. Epidemiol., July 15, 2007; 166(2): 137 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Dasbach, E. H. Elbasha, and R. P. Insinga Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and Disease Epidemiol. Rev., August 1, 2006; 28(1): 88 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Siebert, G. Sroczynski, P. Hillemanns, J. Engel, R. Stabenow, C. Stegmaier, K. Voigt, B. Gibis, D. Holzel, and S. J. Goldie The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany Eur J Public Health, April 1, 2006; 16(2): 185 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Burchell, H. Richardson, S. M. Mahmud, H. Trottier, P. P. Tellier, J. Hanley, F. Coutlee, and E. L. Franco Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada Am. J. Epidemiol., March 15, 2006; 163(6): 534 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Dekker Fostering Acceptance of Human Papillomavirus Vaccines J Am Osteopath Assoc, March 1, 2006; 106(suppl_1): S14 - S18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Legood, A. Gray, J. Wolstenholme, and S. Moss Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies BMJ, January 14, 2006; 332(7533): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Matchar, E. V. Westermann-Clark, D. C. McCrory, M. Patwardhan, G. Samsa, S. Kulasingam, E. Myers, A. Sarria-Santamera, A. Lee, R. Gray, et al. Dissemination of Evidence-based Practice Center Reports Ann Intern Med, June 21, 2005; 142(12_Part_2): 1120 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kim, T. C. Wright, and S. J. Goldie Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst, June 15, 2005; 97(12): 888 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dewilde and R. Anderson The Cost-Effectiveness of Screening Programs Using Single and Multiple Birth Cohort Simulations: A Comparison Using a Model of Cervical Cancer Med Decis Making, October 1, 2004; 24(5): 486 - 492. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Dannecker, U. Siebert, C. J. Thaler, D. Kiermeir, H. Hepp, and P. Hillemanns Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics Ann. Onc., June 1, 2004; 15(6): 863 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, M. Kohli, D. Grima, M. C. Weinstein, T. C. Wright, F. X. Bosch, and E. Franco Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine J Natl Cancer Inst, April 21, 2004; 96(8): 604 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Sawaya, K. J. McConnell, S. L. Kulasingam, H. W. Lawson, K. Kerlikowske, J. Melnikow, N. C. Lee, G. Gildengorin, E. R. Myers, and A. E. Washington Risk of Cervical Cancer Associated with Extending the Interval between Cervical-Cancer Screenings N. Engl. J. Med., October 16, 2003; 349(16): 1501 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Kulasingam and E. R. Myers Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs JAMA, August 13, 2003; 290(6): 781 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Goldie Chapter 15: Public Health Policy and Cost-Effectiveness Analysis J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie and K. M. Kuntz A Potential Error in Evaluating Cancer Screening: A Comparison of 2 Approaches for Modeling Underlying Disease Progression Med Decis Making, May 1, 2003; 23(3): 232 - 241. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, L. Gaffikin, K. K. Limpahayom, P. Lumbiganon, S. Warakamin, J. King, B. Yi, P. Ringers, and P. D. Blumenthal Costs and Benefits of Different Strategies to Screen for Cervical Cancer in Less-Developed Countries J Natl Cancer Inst, October 2, 2002; 94(19): 1469 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Kuntz and S. J. Goldie Assessing the Sensitivity of Decision-Analytic Results to Unobserved Markers of Risk: Defining the Effects of Heterogeneity Bias Med Decis Making, June 1, 2002; 22(3): 218 - 227. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, S. M. Womack, D. Jacobson, B. Yi, Y.-t. Hwang, K. Gold, J. Barter, and K. Shah Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer JAMA, May 8, 2002; 287(18): 2372 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kim, T. C. Wright, and S. J. Goldie Cost-effectiveness of Alternative Triage Strategies for Atypical Squamous Cells of Undetermined Significance JAMA, May 8, 2002; 287(18): 2382 - 2390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, L. Kuhn, L. Denny, A. Pollack, and T. C. Wright Policy Analysis of Cervical Cancer Screening Strategies in Low-Resource Settings: Clinical Benefits and Cost-effectiveness JAMA, June 27, 2001; 285(24): 3107 - 3115. [Abstract] [Full Text] [PDF]
|
|